Onesource Specialty Pharma Stock Price - ₹1,575.70 | Healthcare

‌
‌
‌

The Quarter story

The two most recent quarterly results, compared side-by-side.

OneSource Specialty Pharma shows a clear earnings turnaround with steady deal flow and consistent margins, though past one-off gains have normalized.

Active RFPs in pipeline grow from 25 to 70 from Q1 FY26 to Q1 FY27, signaling sustained deal flow.

Adjusted PAT drops from ₹4.3 to a loss of ₹472 before rebounding to ₹6.7 from Q1 FY26 to Q1 FY27, indicating earnings volatility.

Adjusted EPS climbs from ₹0.04 to ₹5.6 from Q1 FY26 to Q1 FY27, confirming a clear earnings turnaround.

EBITDA surges from ₹10.3 to ₹919 then normalizes to ₹13.1 from Q1 FY26 to Q1 FY27, reflecting the settlement of one-off gains.

New wins increase from 6 to 11 from Q1 FY26 to Q1 FY27, reflecting accelerating commercial traction.

EBITDA margin expands from 27% to 27.5% from Q1 FY26 to Q1 FY27, demonstrating consistent pricing resilience.

Reported PAT recovers from a loss of $2 to $250 from Q1 FY26 to Q1 FY27, highlighting a strong profit recovery.

‌
‌
‌

In the news

India Ratings upgrades Onesource Specialty Pharma to 'A' rating

Onesource Specialty Pharma swings to ₹25 cr Q1 profit, ICICI targets ₹2400

ONESOURCE shares fall 1.59% after strategic biosimilar partnership

Onesource shares fall 7% on Dr Reddy's semaglutide supply delay

Five Stocks to Buy: Pharma, Agrochemical, Telecom & Industrial Picks

Onesource Specialty Pharma gets Unit II expansion approval

OneSource Specialty Pharma shares fall 5% on Q4 profit plunge

Q4 results today: Airtel profit drops 34%, TVS Motor up 37%

OneSource Specialty Pharma gets EU GMP certification for sterile division

Onesource Specialty Pharma partner gets USFDA nod for generic Ozempic

OneSource Specialty Pharma gets EU-GMP renewal for Bengaluru unit

OneSource-Hikma get Saudi Ozempic approval for Middle East market

Onesource Specialty Pharma shares tank 18% on Q3 miss